Pneumocystis jirovecii (formerly known as Pneumocystis carinii) is a fungus found in the lungs of mammals where they reside without causing overt infection unless the host's immune system becomes compromised, at which time an often lethal pneumonia can develop. This fungus is found in humans and animals worldwide. Serologic evidence indicates that most healthy children have been exposed by age 3 to 4. Pneumocystis pneumonia (PCP) occurs in immunosuppressed individuals and in premature, malnourished infants.
Pneumocystis jirovecii is a yeast-like fungus of the genus Pneumocystis. The causative organism of Pneumocystis pneumonia, it is an important human pathogen, particularly among immunocompromised hosts. Prior to its discovery as a human-specific pathogen, P. jirovecii was known as P. carinii.
The complete lifecycles of any of the species of Pneumocystis are not known, but presumably all resemble the others in the genus. The terminology follows zoological terms, rather than mycological terms, reflecting the initial misdetermination as a protozoan parasite. It is an extracellular parasite. All stages are found in lungs and because they cannot be cultured ex vivo, direct observation of living Pneumocystis is difficult. The trophozoite stage is thought to be equivalent to the so-called vegetative state of other species (such as Schizosaccharomyces pombe) which, like Pneumocystis belong to the Taphrinomycotina branch of the fungal kingdom. The trophozoite stage is single-celled and appears amoeboid (multilobed) and closely associated with host cells. Globular cysts eventually form that have a thicker wall. Within these ascus-like cysts, eight spores form which are released through rupture of the cyst wall. The cysts often collapse forming crescent-shaped bodies visible in stained tissue. It is not known for certain if meiosis takes place within the cysts, or what the genetic status is of the various cell types.
Pneumocystis pneumonia is an important disease of immunocompromised humans, particularly patients with HIV, but also patients with an immune system that is severely suppressed for other reasons; for example, following a bone marrow transplant. In humans with a normal immune system, it is an extremely common silent infection.
Identified by methenamine silver stain of lung tissue. Kills type 1 pneumocytes which decrease surfactant and causes death by asphyxiation. Drug of choice is TMP-SMX, pentamidine, or dapsone, make sure to check CD4 Tcell drop below 200.
At first, the name Pneumocystis carinii was applied to the organisms found in both rats and humans, as it was not yet known that the parasite was host-specific. In 1976 the name Pneumocystis jiroveci was proposed for the first time, to distinguish the organism found in humans from variants of Pneumocystis in other animals. The organism was named thus in honor of Czech parasitologist Otto Jirovec, who described Pneumocystis pneumonia in humans in 1952. After DNA analysis showed significant differences in the human variant, the proposal was made again in 1999 and has come into common use.
The name was spelled according to the International Code of Zoological Nomenclature, since the organism was believed to be a protozoan. After it became clear that it was a fungus, the name was changed to Pneumocystis jirovecii, according to the International Code of Botanical Nomenclature (ICBN), which requires such names be spelled with double i (ii). Both spellings are commonly used, but according to the ICBN P. jiroveci has priority. A change in the ICBN in 2005 now recognizes the validity of the 1976 publication, making the 1999 proposal redundant, and cites Pneumocystis and P. jiroveci as examples of the change in ICBN Article 45, Ex 8. The name P. jiroveci is typified (both lectotypified and epitypified) by samples from human autopsies dating from the 1960s. 
The term PCP, which was widely used by practitioners and patients, has been retained for convenience, with the rationale that it now stands for the more general Pneumocystis pneumonia rather than Pneumocystis carinii pneumonia.
The name P. carinii is incorrect for the human variant, but still describes the species found in rats and that name is typified by an isolate from rats.
Pneumocystis species cannot be grown in culture. Therefore, there is a limitation to the availability of the human disease causing agent, P. jiroveci. Hence, investigation of the whole genome of a Pneumocystis is largely based upon true P. carinii available from experimental rats which can be maintained with infections. Genetic material of other species, such as P. jiroveci can be compared to the genome of P. carinii.
The earliest report of this genus appears to have been that of Carlos Chagas in 1909 who discovered it in experimental animals but confused it with part of the life-cycle of Trypanosoma cruzi (causal agent of Chagas disease) and later called both organisms 'Schizotrypanum cruzi' a form of trypanosome infecting humans. The rediscovery of Pneumocystis cysts was reported by Antonio Carini in 1910 also in Brazil. The genus was again discovered in 1912 by Delanoë and Delanoë this time at the Pasteur Institute in Paris, France who found it in rats and who proposed the genus and species name Pneumocystis carinii after Carini.
Pneumocystis was redescribed as a human pathogen in 1942 by two Dutch investigators, van der Meer and Brug who found it in three new cases: a 3-month-old infant with congenital heart disease and in 2 of 104 autopsy cases - a 4-month-old infant and a 21-year-old adult. There being only one described species in the genus, they considered the human parasite to be P. carinii. Nine years later (1951) Dr. Josef Vanek at Charles University in Prague in Prague, Czechoslovakia showed in a study of lung sections from sixteen children that the organism labelled "P. carinii" was the causative agent of pneumonia in these children. The following year (1952) Jírovec reported "P. carinii" as the cause of interstitial pneumonia in neonates. Following the realization that Pneumocystis from humans could not infect experimental animals such as rats, and that the rat form of Pneumocystis differed physiologically and had different antigenic properties, Frenkel was the first to recognize the human pathogen as a distinct species. He named it Pneumocystis jiroveci (see nomenclature above). There has been controversy over the relabeling of P. carinii in humans as P. jiroveci, which is why both names still appear in publications. However, only the name P. jiroveci is used exclusively for the human pathogen, whereas the name P. carinii has had a broader application to many species. Frenkel and those before him believed that all Pneumocystis were protozoans, but soon afterwards evidence began accumulating that Pneumocystis was a fungal genus. Recent studies show it to be an unusual, in some ways a primitive genus of Ascomycota, related to a group of yeasts. Every tested primate, including humans, appears to have its own type of Pneumocystis that is incapable of cross-infecting other host species and has co-evolved with each mammal species. Currently only 5 species have been formally named: P. jiroveci from humans, P. carinii as originally named from rats, P. murina from mice, P. wakefieldiae also from rats, and P. oryctolagi from rabbits.
Historical and even recent reports of P. carinii from humans are based upon older classifications (still used by many, or those still debating the recognition of distinct species in the genus Pneumocystis) which does not mean that the true P. carinii from rats actually infects humans. In an intermediate classification system, the various taxa in different mammals have been called formae speciales or forms. For example the human "form" was called Pneumocystis carinii f. [or f. sp.] hominis, while the original rat infecting form was called Pneumocystis carinii f. [or f. sp.] carinii. This terminology is still used by some researchers. The species of Pneumocystis originally seen by Chagas have not yet been named as distinct species. Many other undescribed species presumably exist and those that have been detected in many mammals are only known from molecular sample detection from lung tissue or fluids, rather than by direct physical observation. Currently, they are cryptic taxa.
- James TY et al. (2006). "Reconstructing the early evolution of Fungi using a six-gene phylogeny". Nature 443 (7113): 818–822. doi:10.1038/nature05110. PMID 17051209.
- "see DPDx life-cycle diagram". Dpd.cdc.gov. Retrieved 2013-03-26.
- Ponce CA, Gallo M, Bustamante R, Vargas SL (2010). "Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population". Clin Infect Dis 50 (3): 347–353. doi:10.1086/649868. PMID 20047487.
- Stringer JR, Beard CB, Miller RF, Wakefield AE (2002). "A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship". Emerg Infect Dis 8 (9): 891–6. doi:10.3201/eid0809.020096. PMC 2732539. PMID 12194762.
- Stringer JR, Beard CB, Miller RF Spelling Pneumocystis jiroveci Emerg Infect Dis. March 2009; doi:10.3201/eid1503.081060
- "ICBN Recommendation 60C.1".
If the personal name ends with a consonant (except -er), substantival epithets are formed by adding -i- (stem augmentation) plus the genitive inflection appropriate to the sex and number of the person(s) honoured (e.g. lecardii for Lecard.
- "ICBN Art. 45.4".
If a taxon originally assigned to a group not covered by this Code is treated as belonging to a group of plants other than algae or fungi, the authorship and date of any of its names are determined by the first publication that satisfies the requirements for valid publication under this Code.
- Redhead SA, Cushion MT, Frenkel JK, Stringer JR (2006). "Pneumocystis and Trypanosoma cruzi: nomenclature and typifications". J Eukaryot Microbiol 53 (1): 2–11. doi:10.1111/j.1550-7408.2005.00072.x. PMID 16441572.
- "Pneumocystis Genome Project". Pgp.cchmc.org. Retrieved 2013-03-26.
- Cissé OH, Pagni M, Hauser PM (2012) De novo assembly of the Pneumocystis jiroveci genome from a single bronchoalveolar lavage fluid specimen from a patient. MBio 4(1). pii: e00428-12. doi:10.1128/mBio.00428-12
- Chagas C (1909). "Neue Trypanosomen". Vorläufige Mitteilung. Arch. Schiff. Tropenhyg. 13: 120–122.
- Chagas C (1909). "Nova tripanozomiase humana: Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem". Mem Inst Oswaldo Cruz 1 (2): 159–218. doi:10.1590/S0074-02761909000200008.
- Carini A. (1910). "Formas des eschizogonia do Trypanosoma lewisi". Soc Med Cir São Paulo 38 (8): –.
- Delanoë P, Delanoë M. (1912). "Sur les rapports des kystes de Carini du poumon des rats avec le Trypanosoma lewisi". Comptes rendus de l'Academie des sciences 155: 658–61.
- van der Meer MG, Brug SL. (1942). "Infection à Pneumocystis chez l'homme et chez les animaux". Amer Soc Belge Méd Trop 22: 301–9.
- Vanek J. (1951). "Atypicka (interstitiálni) pneumonie detí vyvolaná Pneumocystis carinii (Atypical interstitial pneumonia of infants produced by Pneumocystis carinii)". Casop lék cesk 90: 1121–4.
- Jírovec O. (1952). "Pneumocystis carinii puvodce t. zv intertitialnich plasmocelularnich pneumonii kojencw (Pneumocystis carinii, the cause of interstitial plasmacellular pneumonia in neonates)". P Csl. Hyg epid mikrob 1: 141.
- Vanek J, Jírovec O, Lukes J. (1953). "Interstitial plasma cell pneumonia in infants". Ann Paediatrici 180: 1–21.
- Gajdusek DC (1957). "Pneumocystis carinii; etiologic agent of interstitial plasma cell pneumonia of premature and young infants". Pediatrics 19: 543–65.
- Frenkel JK (1976). "Pneumocystis jiroveci n. sp. from man: morphology, physiology, and immunology in relation to pathology". Natl Cancer Inst Monogr 43: 13–27. PMID 828240.
- Gigliotti F (2005). "Pneumocystis carinii: has the name really been changed?". Clin Infect Dis 41 (12): 1752–5. doi:10.1086/498150. PMID 16288399.
- Hawksworth DL (2007). "Responsibility in naming pathogens: the case of Pneumocystis jiroveci, the causal agent of pneumocystis pneumonia". Lancet Infect. Dis. 7 (1): 3–5. doi:10.1016/S1473-3099(06)70663-6. PMID 17182335.
- Hugot J, Demanche C, Barriel V, Dei-Cas E, Guillot J (2003). "Phylogenetic systematics and evolution of primate-derived Pneumocystis based on mitochondrial or nuclear DNA sequence comparison". Syst Biol 52 (6): 735–744. doi:10.1080/10635150390250893. PMID 14668114.
- Keely S, Fischer J, Cushion M, Stringer J (2004). "Phylogenetic identification of Pneumocystis murina sp. nov., a new species in laboratory mice". Microbiology 150 (Pt 5): 1153–65. doi:10.1099/mic.0.26921-0. PMID 15133075.
- Cushion MT, Keely SP, Stringer JR (2004). "Molecular and phenotypic description of Pneumocystis wakefieldiae sp. nov., a new species in rats". Mycologia 96 (3): 429–438. doi:10.2307/3762163. JSTOR 3762163. PMID 21148866.
- Cushion MT, Keely SP, Stringer JR (2005). "Validation of the name Pneumocystis wakefieldiae". Mycologia 97: 268–268. doi:10.3852/mycologia.97.1.268.
- Dei-Cas E et al. (2006). "Pneumocystis oryctolagi sp. nov., an uncultured fungus causing pneumonia in rabbits at weaning: review of current knowledge, and description of a new taxon on genotypic, phylogenetic and phenotypic bases". FEMS Micriobiol. Rev. 30 (6): 853–871. doi:10.1111/j.1574-6976.2006.00037.x. PMID 17064284.
- Aliouat-Denis, C-M. et al. (2008). "Pneumocystis species, co-evolution and pathogenic power". Infection, Genetics and Evolution 8 (5): 708–726. doi:10.1016/j.meegid.2008.05.001. PMID 18565802.
- Demanche C et al. (2001). "Phylogeny of Pneumocystis carinii from 18 Primate Species Confirms Host Specificity and Suggests Coevolution". J. Clinical Microbiol. 39 (6): 2126–2133. doi:10.1128/JCM.39.6.2126-2133.2001. PMC 88100. PMID 11376046.
To request an improvement, please leave a comment on the page. Thank you!